Search results
Start date:
Mar 24, 2026
Dr Kate Gatenby (Leeds Teaching Hospitals NHS Trust, Leeds, UK) will lead this live webinar alongside leading experts to explore the evolving landscape of ATTR CM care with a focus on earlier recognition and confident clinical decision making. The programme will draw attention on emerging evidence, real-world challenges and the growing potential of new treatment approaches including Beyonttra …
View more
Added:
6 months ago
Master the diagnostic complexities of hypertrophic cardiomyopathy (HCM) with Dr Sara Saberi, a leading expert in inherited cardiovascular diseases.This comprehensive presentation, part of the Cardiomyopathies track of Women As One's CLIMB® 2025 Skills Training Program, provides essential insights into the nuanced approach required for accurate HCM diagnosis and risk stratification.Dr Saberi…
View more
Added:
5 months ago
AHA Scientific Sessions 2025 – MAPLE-HCM responder analysis shows aficamten monotherapy led to greater treatment effect when compared to metoprolol monotherapy.Dr Andrew Wang (Duke University Medical Center, Durham, NC, US) presents a responder analysis from the MAPLE-HCM trial (NCT05767346), examining clinical responses to aficamten monotherapy versus metoprolol in patients with obstructive…
View more
Added:
7 months ago
Source:
Transcatheter Academy
The long-term durability of complete revascularization in older patients with myocardial infarction (MI) and multivessel disease has been a subject of recent debate. New 3-year follow-up data from the Functional Assessment in Elderly MI Patients With Multivessel Disease (FIRE) trial show that the clinical benefits of a physiology-guided complete revascularization strategy are sustained over time…
View more
Added:
1 year ago
As part of e-SPACE Cardio-Renal-Metabolic 2024, Dr Paul Stevens discusses 2024 KDIGO guideline updates.
View more
ISHLT 2026
Start date:
Apr 21, 2026
End date:
Apr 25, 2026
Event
Added:
6 months ago
HFSA 25 - Aficamten improves excercise capacity compared to metoprolol in patients with obstructive hypertrophic cardiomyopathy in a prespecified analysis of the MAPLE-HCM study.Dr Gregory Lewis joins us to discuss findings from a prespecified cardiopulmonary exercise testing analysis of the MAPLE-HCM trial, which reveals divergent effects between aficamten and metoprolol on exercise performance…
View more
Added:
1 year ago
In this insightful webinar, Dr Babar Basir (Henry Ford Heart and Vascular Institute, Detroit, MI, US) is joined by Dr Balimkiz Senman (Duke University Hospital, Boston, MA, US) and Prof Jacob Møller (Odense University Hospital, Odense, DE) to delve into the findings of the DanGer Shock trial, recently presented at the American College of Cardiology (ACC) Conference in April 2024. This session…
View more
Added:
7 months ago
Source:
Arrhythmia Academy
A strategy of actively increasing plasma potassium to high-normal levels significantly lowered the risk of arrhythmia events in high-risk patients with an implantable cardioverter–defibrillator (ICD), according to results from the POTCAST trial.¹˒² The findings were presented at the European Society of Cardiology (ESC) Congress 2025 and simultaneously published in the New England Journal of…
View more
Added:
1 year ago
Intra-operative 4-chamber transesophageal echo (TEE) view: Intraoperative TEE in 4-chamber view showing a highly mobile mass with near cavity obliteration of the LA.
View more